AUTOMATED PERITONEAL DIALYSIS DEVICE, SYSTEM AND METHOD OF CUSTOMIZING DIALYSATE SOLUTIONS
20210038798 ยท 2021-02-11
Inventors
- Steve J. Lindo (Chicago, IL, US)
- Richard A. Pendergraft (Norman, OK, US)
- Jacob Henderson (Oklahoma City, OK, US)
- Erika Mallery (Oklahoma City, OK, US)
- Alexandra Arment (Thorton, CO, US)
Cpc classification
A61M1/1605
HUMAN NECESSITIES
A61M1/155
HUMAN NECESSITIES
A61M2205/52
HUMAN NECESSITIES
International classification
Abstract
An automated peritoneal dialysis (APD) device, system and method is provided, which utilizes mechanisms to admix customized dialysate solutions from multiple sources, while maximizing volumetric accuracy. The present automated peritoneal dialysis (APD) device can accomplish these goals all within the convenience and comfort of the patient's home utilizing filtered tap water.
Claims
1. A device for creating a customized peritoneal dialysis solution and administering peritoneal dialysis to a patient, the device comprising: a unit housing; a cassette housing disposed within the unit housing; a cassette contained within the cassette housing; at least one pump chamber formed within the cassette; a plurality of inlet ports and outlet ports connected to the cassette, the inlet ports and outlet ports fluidly connected to the at least one pump chamber; at least one valve for selectively sealing off and re-opening fluid communication between any one or more of the inlet ports and the at least one pump chamber and the outlet ports and the at least one pump chamber; a plurality of inlet lines and outlet lines connected to the inlet ports and outlet ports, the inlet lines and outlet lines connected to a plurality of bags containing liquid components for creating a dialysate solution; wherein the at least one pump chamber within the cassette is configured to withdraw and measure a volume of a selected quantity of liquid components from the bags and deliver a selected volume of the chosen liquid to a receptacle to allow the mixing together of selected quantities of the liquid components to provide a dialysis solution of a desired final formulation; and, a pneumatic manifold contained within the unit housing, the pneumatic manifold fluidly connected to the cassette housing and configured for controlling the mixing of the liquid components within the pump chamber.
2. The device of claim 1, wherein the cassette includes at least two pump chambers.
3. The device of claim 1, wherein the cassette comprises a concave surface covered by a flexible plastic sheeting.
4. The device of claim 3, wherein the flexible plastic sheeting closes and opens the valves thereby controlling fluid communication between the bags containing the liquid components to the pump chamber and then to the receptacle.
5. The device of claim 1, wherein the pneumatic manifold further comprises multiple air accumulators connected to the pneumatic manifold.
6. The device of claim 6, wherein the pneumatic manifold further comprises a plurality of solenoid valves and pressure transducers configured to operate and regulate the air flow from the air accumulators for operation of the cassette.
7. The device of claim 1, wherein the pneumatic manifold further comprises multiple air accumulators and an air pump connected to the pneumatic manifold.
8. The device of claim 7, wherein the pneumatic manifold further comprises a plurality of solenoid valves and pressure transducers configured to operate and regulate the air flow from the air accumulators.
9. The device of claim 1, wherein the receptacle is an admixing bag configured for receiving the dialysate solution components as mixed together from the cassette prior to administering to the patient.
10. The device of claim 9, wherein the admixing bag is fluidly connected to the patient through a catheter.
11. A method for creating a customized peritoneal dialysis solution and administering the solution to a patient, the method comprising the steps of: providing a plurality of bags containing solution components for creating a dialysis solution; providing a fluid mixing cassette assembly having a plurality of inlet ports and outlet ports; connecting a plurality of lines to the inlet ports and the outlet ports of the cassette each to the respective bags of dialysate solution components; mixing a selected volume of each of the dialysate solution components withdrawn from the respective bag in the fluid mixing cassette assembly; creating a customized dialysate solution having a desired final composition; delivering the customized dialysate solution to a receptacle for administering to a patient.
12. The method of claim 11 wherein the selected volume of dialysate solution components is cycled back and forth from a mixing container to the cassette multiple times to agitate and homogenize the fluid.
13. The method of claim 11 wherein the method further includes using a pneumatic electronic control assembly to operate the fluid mixing cassette assembly.
14. The method of claim 11 wherein the method further includes determining a sodium concentration based on a volume of a sodium solution delivered to the mixing container relative to the volume of the other ingredients delivered to the mixing container.
15. The method of claim 14 wherein the method further includes preventing the system from administering to the patient if the calculated final sodium concentration falls outside of pre-defined safe limits.
16. The method of claim 15 wherein the method further includes determining a potassium concentration based on a volume of potassium solution delivered to the mixing container relative to the volume of the other ingredients delivered to the mixing container.
17. The method of claim 16 wherein the method further includes preventing the system from administering to the patient if the calculated final potassium concentration falls outside of pre-defined safe limits.
18. A method for determining an appropriate peritoneal dialysis prescription tailored to meet treatment needs of a patient, the method comprising the steps of; providing an input computing device; inputting patient health parameters into the computing device; using the computing device to calculate a concentration of electrolytes for the solution based in the patient health parameters; inputting the calculated concentration of electrolytes into an automated peritoneal dialysis (APD) device; mixing the concentration of electrolytes in the APD device into a solution suitable for administration to the patient; and, administering the solution to the patient.
19. The method of claim 18, wherein the electrolytes are at least one of sodium or potassium.
20. The method of claim 19, wherein the method further includes removing a determined quantity of sodium from the patient's bloodstream or adding a determined quantity of potassium to the patient's bloodstream with each treatment.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0037] The drawing figures depict one or more implementations in accord with the present concepts, by way of example only, not by way of limitations. In the figures, like reference numerals refer to the same or similar elements.
[0038]
[0039]
[0040]
[0041]
[0042]
[0043]
[0044]
[0045]
DETAILED DESCRIPTION
[0046] The automated peritoneal dialysis (APD) device and system of the present disclosure, in the preferred embodiments, utilizes mechanisms to admix customized dialysate solutions from multiple sources, while maximizing volumetric accuracy. The present automated peritoneal dialysis (APD) device can accomplish these goals all within the convenience and comfort of the patient's home utilizing filtered tap water.
[0047]
[0048] As shown in in
[0049]
[0050] As further illustrated in
[0051]
[0052] The pump chambers 32 are formed by a concave rigid cassette body 33 covered on both sides by flexible plastic sheeting 34. When appropriate pneumatic pressure from the pneumatic manifold 16 is applied to the flexible plastic sheeting 34, the fluid within the pump chamber 32 is forced out as the sheeting bends to approach or touch the hard plastic pump chamber's concave base 33. Fluid is drawn into the pump chamber 32 by applying negative (vacuum) pressure to the outer surface of the flexible sheeting 34.
[0053] The disposable cassette 30 acts like a two-story house, with some fluid paths routed on the top story or top section 30a of the chamber 32, while other fluid paths routed on the bottom story or bottom section 30b of the chamber 32, with a piece of rigid plastic 30c separating the top and bottom story, and strategically placed through holes 30d connecting the two stories or sections. Each pump chamber 32 has holes 30d to allow fluid to be routed to or from the top 30a or bottom 30b of the chambers, depending on the fluid source. The drain line DL is routed to the top section 30a such that air, when partially purged, will exit to the drain. The patient line P is routed to the bottom section 30b to avoid delivery of air when the pump chamber's contents are partially delivered to the patient. In this manner, the cassette's pump chambers 32 can hold a certain volume of air. The volume of each pump chamber 32 is larger than the holdup volume of the tubing going from the cassette 30 to the admix bag 114 (
[0054] The APD disposable cassette 30 utilizes multiple valves 31, as referred to as volcano valves, to control fluid routing to and from each of the following 9 sources: Patient, Drain, Admix Bag, Sterilized Water, Dextrose Bag Concentration A, Dextrose Bag Concentration B, Saline/Potassium Bag, Buffer Bag, and Last Fill Bag. The Saline Bag may consist of normal saline (0.9%) or hypertonic saline (3% or 5%). The Potassium Bag may consist of highly concentrated potassium chloride in water for injection, potassium chloride in normal saline (0.9%), or potassium chloride in 5% dextrose and saline, all currently commercially available. All sources listed as bags could alternatively be lyophilized powders in vials or similar containers. The powders may be reconstituted by the APD device by routing sterilized water to the vial or container, then drawing from the vial or container prior to delivery.
[0055]
[0056] As shown in the schematic of
[0057]
[0058] The governing equations are shown below:
PV=nRT(Ideal Gas Law), or rearranging, n=PV/RT
There are two sides containing air, the disposables side, designated as d, and the reference chamber side, designated as r. Each side has an initial state, designated by i, and a final state after pressures between the two sides have been essentially equalized, designated by f.
[0059] The number of moles of air on the disposables side in the initial state is calculated as:
where V.sub.d is the unknown volume of the disposables side to calculate.
[0060] The number of moles of air on the reference chamber side in the initial state is calculated as:
where V.sub.r is the volume of air in the reference chamber, which is a known, fixed value.
[0061] The number of moles of air on the disposables side in the final state is calculated as:
[0062] The number of moles of air on the reference chamber side in the final state is calculated as:
[0063] Since the total number of moles of both sides put together remains constant (air is simply shuffled from one side to the other as pressure is released from the reference chamber to the disposables side), the formula is the following:
n.sub.di+n.sub.ri=n.sub.df+n.sub.rf
[0064] Therefore, by substitution, the calculation is the following:
[0065] The R term cancels out. Rearranging, the calculation is:
[0066] Solving for Vd, the calculation is:
This is the equation that governs the volume calculations if using temperature measurement.
[0067] However, if temperature of the reference chamber and the disposables side are held in thermal contact with each other such that they are essentially constant, the equation simplifies as:
[0068] Additional temperature compensation via direct temperature measurement of the volume reference chamber and/or pump chamber may be added to increase volumetric accuracy, since the Ideal Gas Law calculates volume as a function of pressure and temperature as described above.
[0069] Alternatively, the temperature of the volume reference chamber may be held quasi-constant at or near body temperature by placing the volume reference chamber in thermal contact with the cassette's pump chamber and/or by including a thermally conductive wire mesh material inside the volume reference chamber to provide a high degree of surface area for quickly stabilizing the gas temperature within the volume reference chamber even after a rapid temperature excursion due to rapid pressure changes within the reference chamber. In this alternative, no temperature measurement is necessary.
[0070]
[0071] In the past, clinicians have not been able to customize the sodium or potassium used in APD therapy. Clinicians currently have PC-based software tools to determine how to prescribe the dextrose concentration and dwell times in order to remove a certain volume of ultrafiltration, but they do not have any tools to help them prescribe the sodium concentration and dwell times in order to remove a certain quantity of sodium from the patient's bloodstream with each therapy. These existing prescription optimization tools have historically been based on kinetic modeling of solute transport across the peritoneum. The present disclosure further includes an easy-to-use therapy software that will aid clinicians in the selection of optimized sodium, potassium, and glucose concentrations based on a patient's specific health factors, so that clinicians will easily be able to use the present APD device for optimal patient outcomes.
[0072] As illustrated in
[0073] For example, the present APD device 10 and system 100 utilizes the PC-based software application 200 to estimate the amount of dextrose to deliver to the patient as a function of the sodium content. Since both dextrose and sodium are osmotic agents, if a patient is given a lower-than-normal sodium dialysate solution, the dextrose concentration must be adjusted upward in order to maintain the same equivalent osmotic gradient as a normal sodium (i.e. 132-134 mmol/l) dialysate solution would have had. An advantage of the present software application 200 is that the software will calculate the sodium (or potassium) concentration to deliver, based on the user-entered desired weekly or daily sodium removal (or potassium addition) target, along with the patient's physical characteristics 201 such as peritoneal transport type (High, High Average, Low Average, or Low), body surface area, and blood sodium (or potassium) concentration.
[0074] The software application 200 will also automatically calculate the concentration of dextrose and volume to deliver from each of the source containers, based on the sodium concentration and ultrafiltration (UF) targets, to achieve the same osmolality of the equivalent normal sodium (or potassium) concentration and normal dextrose concentration solution that would be needed to achieve those UF targets. This software application 200 could be installed on the clinician's PC 202 and/or be accessible via web browser.
[0075] The known 3-pore kinetic model of peritoneal dialysis may be used to estimate therapy outcomes based on the solution concentrations and patient's body characteristics. For example, the present software application 200 and/or the ADP device 10 programming screens will calculate the appropriate sodium removal or potassium addition prescription for an individual patient. As shown in
[0076] Yet another advantage in utilizing the present software application 200 is that the final clinician-approved dialysis prescription can then be remotely downloaded to the APD device 10 such that the patient does not have to manually enter each of the prescription parameters on the APD device's user interface. This prescription could be adjusted regularly as needed, based on new blood measurements that occur approximately once per month, using the same input parameters 201 shown in
OPERATION AND EXAMPLES
[0077] In operation, and by way of example, the present APD device 10 and system 100 envisions two concentrated dialysate dextrose solutions, Dextrose A and Dextrose B, intended to be mixed in various proportions to produce an intermediate dextrose concentration after dilution with sterile water, hypertonic saline, and buffer solution. Dextrose A is intended to produce 1.0% dextrose solution at 100 mEq/l after dilution, while Dextrose B is intended to produce 4.5% dextrose at 100 mEq/l after water dilution and before any hypertonic saline addition. Both Dextrose A and Dextrose B would contain 30% Dextrose Hydrous.
[0078] Dextrose A, in one embodiment, would contain the following composition per 100 ml: Dextrose Hydrous 30.0 g, Calcium Chloride Dihydrate (CaCl.sub.2.2H.sub.2O) 552.0 mg, Magnesium Chloride Hexahydrate (MgCl.sub.2.6H.sub.2O) 153.0 mg.
[0079] Dextrose B, in one embodiment, would contain the following composition per 100 ml: Dextrose Hydrous 30.0 g, Calcium Chloride Dihydrate (CaCl.sub.2.2H.sub.2O) 122.7 mg, Magnesium Chloride Hexahydrate (MgCl.sub.2.6H.sub.2O) 34.0 mg.
[0080] The Buffer Solution, in one embodiment, would contain the following composition per 100 ml: Sodium Chloride 7014 mg, Sodium Lactate (C.sub.3H.sub.5NaO.sub.3) 3360 mg, Sodium Bicarbonate (NaHCO.sub.3) 4200 mg.
[0081] A 200 ml container of Dextrose A, after dilution with a 300 ml container of Buffer Solution and 5500 ml of sterile water, would yield the following solution composition per 100 ml: Dextrose Hydrous 1.0 g, Sodium Chloride (NaCl) 350.7 mg, Sodium Lactate (C.sub.3H.sub.5NaO.sub.3) 168 mg, Calcium Chloride Dihydrate (CaCl.sub.2.2H.sub.2O) 18.4 mg, Magnesium Chloride Hexahydrate (MgCl.sub.2.6H.sub.2O) 5.10 mg, Sodium Bicarbonate (NaHCO.sub.3) 210 mg.
[0082] A 900 ml container of Dextrose B, after dilution with a 300 ml container of Buffer Solution and 4800 ml of sterile water, would yield the following solution composition/100 ml: Dextrose Hydrous 4.5 g, Sodium Chloride (NaCl) 350.7 mg, Sodium Lactate (C.sub.3H.sub.5NaO.sub.3) 168 mg, Calcium Chloride Dihydrate (CaCl.sub.2.2H.sub.2O) 18.4 mg, Magnesium Chloride Hexahydrate (MgCl.sub.2.6H.sub.2O) 5.10 mg, Sodium Bicarbonate (NaHCO.sub.3) 210 mg.
[0083] The admixing of Dextrose A, Dextrose B, Buffer Solution, and Sterile Water could be augmented by further admixing hypertonic saline in one embodiment to increase the sodium concentration from 100 mEq/l to any intermediate value up to and including 170 mEq/l. The volume of sterile water used for dilution is reduced by the corresponding amount of hypertonic saline added. As an example if a dextrose concentration of 2.0% and a sodium concentration of 110 mEq/l is desired (rather than 100 mEq/l), an additional 117 ml of 3% hypertonic saline would be added to 143 ml of Dextrose A, 257 ml of Dextrose B, and 300 ml of Buffer Solution, and 5183 ml of sterile water to create 6000 ml of admixed solution.
[0084] In another example, the present APD device 10 utilizes similar ultra-low sodium solutions as the previous paragraph, except without the use of buffer solutions. Again, both Dextrose A and Dextrose B would contain 30% Dextrose Hydrous.
[0085] Dextrose A, in one embodiment, would contain the following composition per 100 ml: Dextrose Hydrous 30.0 g, Sodium Chloride 10523 mg, Calcium Chloride Dihydrate (CaCl.sub.2.2H.sub.2O) 552.0 mg, Magnesium Chloride Hexahydrate (MgCl.sub.2.6H.sub.2O) 153.0 mg.
[0086] Dextrose B, in one embodiment, would contain the following composition per 100 ml: Dextrose Hydrous 30.0 g, Sodium Chloride 2339 mg, Calcium Chloride Dihydrate (CaCl.sub.2.2H.sub.2O) 122.7 mg, Magnesium Chloride Hexahydrate (MgCl.sub.2.6H.sub.2O) 34.0 mg.
[0087] A 200 ml container of Dextrose A, after dilution with 5800 ml of sterile water, would yield the following solution composition per 100 ml: Dextrose Hydrous 1.0 g, Sodium Chloride (NaCl) 350.8 mg, Sodium Lactate (C.sub.3H.sub.5NaO.sub.3) 448 mg, Calcium Chloride Dihydrate (CaCl.sub.2.2H.sub.2O) 18.4 mg, Magnesium Chloride Hexahydrate (MgCl.sub.2.6H.sub.2O) 5.10 mg.
[0088] A 900 ml container of Dextrose B, after dilution with 4100 ml of sterile water, would yield the following solution composition per 100 ml: Dextrose Hydrous 4.5 g, Sodium Chloride (NaCl) 350.8 mg, Sodium Lactate (C.sub.3H.sub.5NaO.sub.3) 448 mg, Calcium Chloride Dihydrate (CaCl.sub.2.2H.sub.2O) 18.4 mg, Magnesium Chloride Hexahydrate (MgCl.sub.2.6H.sub.2O) 5.10 mg.
[0089] The admixing of Dextrose A, Dextrose B, and Sterile Water could be augmented by further admixing hypertonic saline in one embodiment to increase the sodium concentration from 100 mEq/l to any intermediate value up to and including 170 mEq/l. The volume of sterile water used for dilution is reduced by the corresponding amount of hypertonic saline added. As an example if a dextrose concentration of 2.0% and a sodium concentration of 110 mEq/l is desired (rather than 100 mEq/l), an additional 117 ml of 3% hypertonic saline would be added to 143 ml of Dextrose A, 257 ml of Dextrose B, and 5483 ml of sterile water to create 6000 ml of admixed solution.
[0090] It should be noted that various changes and modifications to the presently preferred embodiments described herein will be apparent to those skilled in the art. Such changes and modifications may be made without departing from the spirit and scope of the present invention and without diminishing its attendant advantages.